Windlas Biotech Ltd. launched its Rs 401.5-crore initial public offering on Aug. 4. as the contract drugmaker aims to expand capacity and lower debt.
The company will sell shares at Rs 448-460 apiece, seeking a market value of Rs 1,002.5 crore at the upper end of the price band. The IPO comprises a fresh issue of Rs 165 crore and an offer-for-sale worth Rs 236.5 crore by the promoter group and Tano India Private Equity Fund-II.
The company plans to use Rs 50 crore to expand capacity of its existing facility at Dehradun (plant 4) and its injectables dosage capability at Dehradun (plant 2). It also aims to retire long-term debt worth Rs 20 crore and fund incremental working capital requirements of Rs 48 crore. The rest will be used for general corporate purposes.
Prior to the IPO, Windlas Biotech had raised Rs 120.46 crore by allotting more than 26 lakh shares to 22 anchor investors at the upper end of the price band.
Besides Windlas Biotech, Exxaro Tiles Ltd., Krsnaa Diagnostics Ltd. and Devyani International Ltd. launched their maiden offers on Aug. 4. The IPOs will close on Aug. 6.
Subscription Details: Day 1
The IPO was subscribed 3.18 times as of 5 p.m. on Aug. 4.
Institutional investors: 0.00 times
Non-institutional investors: 0.34 times
Retail investors: 6.22 times
Research Reports On Windlas Biotech IPO
Watch BloombergQuint's IPO Adda with Windlas Biotech:
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
